We retrospectively compared the incidence and clinical characteristics of cGVHD in 37 allo-PBT recipients transplanted between July 1994 and October 1996 and 37 historical control allo-BMT recipients in a casecontrol study. All patients received a first unmanipulated transplant, graft from an HLA-identical sibling donor, with CsA-MTX GVHD prophylaxis and survived more than 100 days after transplant. PBT and BMT groups were well matched for age, grade of acute GVHD, male patients grafted from female donors, and phase of disease. The median CD34
Allogeneic peripheral blood progenitor cell transplantation (allo-PBT) is being used more frequently instead of allogeneic bone marrow transplantation (allo-BMT). The reasons for this increase include the safe and easier collection of hemopoietic progenitor cells in the donor, and rapid neutrophil and platelet engraftment. [1] [2] [3] Among the potential disadvantages, severe aGVHD seem not to be increased, [4] [5] [6] [7] [8] and late bone marrow failure 9 and the possibility of unknown long-term effects of G-CSF in donors, has not been observed. [10] [11] [12] Of concern, some preliminary results suggest that the incidence of chronic GVHD (cGVHD) might be higher. [13] [14] [15] [16] [17] Until now, few PBT clinical studies reported have had a sufficient follow-up to address this question and there are no published randomized studies addressing this issue. We have performed a case-control retrospective comparison of the incidence of cGVHD between allo-PBT and allo-BMT. All patients included in the analysis, received non-T cell-depleted allografts from an HLA-matched sibling donor and survived more than 100 days after stem cell transplantation. Analysis was focused on: (1) probability of developing cGVHD; (2) its clinical manifestations; and (3) risk factors for developing cGVHD.
Patients and methods

Patients
Patients included in the present analysis were retrospectively selected from those with hematological malignancies who underwent allo-PBT in eight Spanish centers as part of individual studies to determine the feasibility and complications related to this type of transplant. Thirty-seven patients were selected because they fulfilled the following criteria: ages between 18 and 60 years, no major organ dysfunction, Karnofsky scores greater than 80%, HLAidentical sibling donors, non-T cell-depleted grafts, first transplants, GVHD prophylaxis with standard CsA plus MTX, survival for more than 100 days with sustained engraftment. Patients and donors were asked to participate in the study and signed informed consent forms. Patient characteristics are listed in Table 1 . 1st phase = 1st remission or 1st chronic phase; 2nd phase = diseases in remission beyond first remission or chronic phase; 3rd phase = partial remission or resistant disease.
Historical control group
We selected one control patient treated with allo-BMT for each allo-PBT patient from a historical BMT database of patients most recently transplanted in the same hospitals. For matching, every patient in the allo-BMT group shared the following characteristics with the corresponding patient in the allo-PBT group: [18] [19] [20] age (interval of ±5 years), grade of previous acute GVHD, male patient with female donor (whether or not she had borne children), and phase of disease. Control patient characteristics are listed in Table 1 .
Preparative regimen
All patients in both groups ( ). Conditioning was followed by the infusion of a non-cryopreserved apheresis product (PBT group) or bone marrow (BMT group) as the sole source of stem cells.
Engraftment
Blood counts were performed daily until discharge from hospital and then at least once a week for the first 3 months. Granulocyte engraftment was defined as the first of 3 consecutive days with an ANC у0.5 × 10 9 /l. Platelet engraftment was defined as the first of 2 consecutive days with an unsupported count у20 × 10 9 /l. 
Supportive care
GVHD prophylaxis consisted of intravenous CsA (3 mg/kg, every 12 h from day −1), followed by oral CsA (6.25 mg/kg every 12 h) when tolerated. All patients were scheduled to continue the same dose of CsA until day +60, with progressive tapering thereafter, until cessation on day +180. Methotrexate was administered to all patients: 15 mg/m 2 intravenously on day 1, followed by 10 mg/m 2 on days 3, 6 (n = 20 and n = 9, in PBT and BMT, respectively), or days 3, 6, 11 (n = 17 and n = 28, in PBT and BMT, respectively). Treatment characteristics are listed in Table 2 .
G-CSF (filgrastim; Amgen, Thousand Oaks, CA, USA) 5 g/kg/day by subcutaneous injection was given posttransplant beginning on day 0 until the ANC was greater than 1 × 10 9 /l for 3 consecutive days in nine patients (24%) of the PBT group and in two patients (5%) in the BMT group. Single-donor or random platelet transfusions were administered for a platelet count less than 20 × 10 9 /l, and RBC transfusion for a hemoglobin level less than 8.0 g/dl. All cellular blood products received gamma-irradiation (2 Gy) before transfusion.
All patients received infection prophylaxis from hospital admission with ciprofloxacin 500 mg twice daily p.o., fluconazole 200 mg twice daily p.o., and acyclovir 200 mg, 4 times daily p.o.
Intravenous broad-spectrum antibiotics were initiated for an ANC less than 0.5 × 10 9 /l and fever greater than 38°C.
GVHD diagnosis
Diagnosis and grading of acute and chronic GVHD were established according to the Seattle criteria. 21 Biopsy confirmations of at least one of the affected organs was required. When skin was affected in addition to other locations, histological review of oral or skin biopsies was used to diagnose and to assess response to therapy.
Chronic GVHD was defined as GVHD present after day 90. cGVHD was considered as progressive when it appeared as a continuation of previous clinical grade I-IV aGVHD; cGVHD was defined as de novo when there was no previous aGVHD; and quiescent when it reappeared after a response from previous aGVHD. 
Stem cell collection and processing
In the PBT group, all 37 healthy donors received G-CSF (filgrastim; Amgen) at a median dose of 10 g/kg/day by subcutaneous injection for 5 to 8 days. On day 5 after starting G-CSF, donors underwent a 10-20 l leukapheresis on a continuous flow cell separator. Leukaphereses were performed daily until a minimum of 2 × 10 6 CD34 + cells/kg recipient weight had been collected from each donor. Cells were maintained at 4°C until infusion.
In the BMT group, bone marrow was harvested from the posterior iliac crests using established methods. 23 
Study design and statistical methods
This was a pair-matched case-control multi-center analysis. The primary outcome was to compare the incidence of chronic GVHD in both groups. Comparisons of the differences in distribution were tested using the Mann-Whitney test. Distribution of time-to-event data was estimated using the Kaplan-Meier method 22 and compared statistically using the log-rank test. Estimates of the incidence of GVHD were also obtained using cumulative incidence 23 in which death or relapse without chronic GVHD were considered a competing risk. Analysis of variables that were potential prognostic factors for cGVHD was performed with the Cox's proportional hazard method. 24 Statistical analyses were done with the SPSS statistical software.
Results
Donors and characteristics of PB collections
G-CSF administration was well tolerated except for moderate bone pain occurring in all donors. Leukapheresis procedures were performed without complications through a peripheral vein in all donors. The median number of cells collected (×10 /l, was significantly less after PBT than after BMT (Table 3 ). Day after transplant
Probability of cGVHD Figure 1 Actuarial probability for chronic GVHD after PBT (dotted line) or BMT (solid line) groups, P = 0.01. X axis is expressed in log scale. Ticks, censored cases. Day after transplant Cumulative incidence of cGVHD 
Incidence of cGVHD
The median follow-up was 12.3 months (range 5.4-30.3) and 58.7 months (range 4-122), for patients receiving PBT and BMT, respectively. In the PBT group, 15 patients died, 13 (87%) because of relapse, and two patients (13%) because of cGVHD itself or its treatment. Twenty patients are alive in remission and two are alive with leukemic relapse. In the BMT group 12 patients died, nine (75%) because of relapse, one patient (12%) because of cGVHD itself or its treatment, one patient (8%) because of infectious complications without GVHD or relapse, and one patient because of sudden death. Twenty-three patients are alive in remission and two patients are alive with leukemic relapse.
Of the 37 patients who received PBT, acute GVHD was clinical grade 0 (n = 14, 38%), I (n = 13, 35%), II (n = 5, 13.5%), and III (n = 5, 13.5%). Since previous acute GVHD was one of our controlled variables, the BMT group had the same incidence and severity ( Table 4) . The 1 year actuarial probability for cGVHD was 59% (95% CI 39-79) and 27% (95% CI 12-42), for patients receiving PBT and BMT respectively (P = 0.01) (Figure 1 ). Cumulative incidence estimate of cGVHD was 51% and 25%, for patients receiving PBT and BMT respectively (P = 0.03). The median day of onset of cGVHD from transplant was 148 (range 91-360) after PBT, and 192 (range 88-369) after BMT. The type and characteristics of cGVHD are summarized in Table 4 . Presentation was progressive in four patients (24%), de novo in eight patients (47%) and quiescent in five patients (29%).
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In the PBT group, 11 patients were alive without cGVHD after a median time of 322 days (range 162-636) post-transplantation.
Risk factors for cGVHD in the PBT group
The following variables were included into the univariate analysis in order to determine their influence in the occurrence of cGVHD: age of the patient (four groups were used: less than 30, 31 to 40, 41 to 50 and more than 50 years) (P = 0.5), age of the donor (four groups were used: less than 30, 31 to 40, 41 to 50 and more than 50 years) (P = 0.7), number of CD3 + (four groups were used: less than 25th percentile, 25th to 50th, 50th to 75th and more than 75th percentile of the number of CD3 + cells infused) (P = 0.5), and CD34 + (four groups were used: less than 25th percentile, 25th to 50th, 50th to 75th and more than 75th percentile of the number of CD34 + cells infused) (P = 0.8) infused cells, type of GVHD prophylaxis (3 vs 4 doses of methotrexate) (P = 0.4), male recipient from female donor status (P = 0.2), diagnosis (P = 0.8), phase of disease (P = 0.2), and type of conditioning treatment (BUCY vs TBI plus cyclophosphamide) (P = 0.3). CMV status was not included in the analysis because more than 90% of our patients and donors were CMV positive. Only the presence of previous acute GVHD influenced the appearance of cGVHD (P = 0.009). This complication was present in four of 14 (28.5%) patients without previous aGVHD, in nine of 18 (50%) with aGVHD clinical grades I-II, and in four of five (80%) with grade III. The multivariate analysis, which included patient age, male patient and female recipient status, the number of CD3
+ and the number of CD34 + cells infused, diagnosis, disease phase at transplant, type of conditioning and presence of previous acute GVHD, determined that only the last factor significantly increased the risk of cGVHD. The chance of developing clinical cGVHD by 1 year was 4.4 times higher among PBT than BMT recipients (95% confidence interval, 1.2 to 16.4; P = 0.03) ( Table 5) .
Clinical manifestations of cGVHD
In the PBT group, all patients with cGVHD, developed skin and/or mucous (oral lichenoid lesions or oral/conjuntival dryness) involvement. Eleven out of the 17 patients (65%), demonstrated combined skin and liver involvement. Two patients developed obstructive pulmonary disease, and in one case only intestinal (small bowel) involvement was observed. In the cases with liver involvement, a predominance of cholestatic pattern was observed. In the BMT group, eight out of the nine patients (89%) with cGVHD developed skin and/or mucous involvement. Four of the nine patients (44%) developed combined skin and liver involvement, and three patients developed obstructive pulmonary disease (Table 4) . The presence of cGVHD had no negative impact on overall survival, in either the PBT (P = 0.2) or BMT (P = 0.8) groups.
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Response to treatment
In the PBT group, CsA and steroids (n = 15) or steroids (n = 2) were used initially for cGVHD treatment, for a median of 135 days (range 16-300). Complete disappearance of all clinical manifestations of cGVHD was observed in five (29%) patients. A partial improvement was obtained in 10 cases, and these patients continued on therapy at the time of the analysis. Three patients showed no response to initial or subsequent treatment. Thalidomide was added for one patient, with no response at the time of the analysis after 2 months of treatment. Two patients with cutaneous, hepatic and intestinal presentation died due to infectious complications secondary to cGVHD or its treatment.
In the BMT group, CsA and steroids (n = 5) or steroids (n = 4) were used initially for cGVHD treatment, for a median of 495 days (range 270-720). Complete disappearance of all clinical manifestations of cGVHD was observed in five (55.5%) patients. A partial improvement was seen in two patients, who continued on therapy at the time of the analysis. Two patients showed no response to the treatment. Thalidomide was added to the treatment in one patient, without improvement at the time of the analysis. The second patient received azathioprine, with partial improvement. One patient died due to infectious complications secondary to treatment of non-responding hepatic cGVHD.
Discussion
Preliminary non-comparative studies have suggested that allogeneic non-T cell-depleted PBT mobilized by growth factors is associated with earlier hematological and immune reconstitution and a similar incidence of aGVHD, when compared to allo-BMT. [13] [14] [15] [16] [17] The rapid hematopoietic recovery is to be expected because of the high number of progenitors cells infused in the graft, which is two to three times more than that present in the bone marrow graft, in addition to a different composition of hematopoietic cells. In contrast, aGVHD is not increased as would be predicted by the abundance of T cells in the PB graft. Moreover, it has been stated that once the 10 5 /kg threshold has been exceeded, the differences in minor HLA antigens rather than the amount of donor T-lymphocytes would be a more important determinant for the development of aGVHD. 25, 26 Recent hypotheses suggest that aGVHD occurring after allo-BMT is the result of cytokine dysregulation induced by damage and activation of host tissue because of the transplant conditioning regimen; 27 this could offset, at least in part, the importance of the absolute number of donor T cells.
Other possible explanations for a similar incidence of aGVHD in PBT include the presence in the graft of a large number of G-CSF-stimulated monocytes with T cell suppressor activity, 28, 29 and a G-CSF induced shift of T cells towards a T helper type-2 (Th2) phenotype which has been associated with secretion of anti-inflammatory cytokines and decrease of TNF activity. It has been hypothesized that the activation of donor T cells that secrete type-1 cytokines (Th1) preferentially induces aGVHD, whereas the activation of those that secrete type-2 cytokines (Th2) would lead to cGVHD. [30] [31] [32] [33] These events could explain why the incidence of aGVHD is similar in allo-PBT when compared to allo-BMT, whereas the incidence of cGVHD could be higher.
A classical study from Storb et al 19 registered an increased incidence of cGVHD associated with an increment in the number of lymphoid cells in patients with aplastic anemia. In this study, multiply transfused patients where given unirradiated buffy-coat cells from the marrow donor, in addition to bone marrow, in order to increase the number of stem cells, and provide donor lymphoid cells, which may be beneficial in enhancing hematopoietic engraftment. This approach reduced the incidence of graft rejection, but was associated with a high incidence of cGVHD.
In accordance with a recent study, 31 the results presented here suggest that the incidence of cGVHD after allo-PBT may be higher than after allo-BMT. Seventeen out of 37 (46%) PBT patients in our series developed cGVHD. The 1 year actuarial probability of cGVHD was 59% in the PBT group vs 31% in the allo-BMT group. This incidence of cGVHD after allo-PBT is comparable to results from Anderlini et al 14 and Majolino et al, 13 and to other preliminary results. 15, 16 A higher incidence of this complication in comparison with allo-BMT was not found in other allo-PBT studies, [34] [35] [36] [37] [38] including two 35, 36 in which an historical group of patients transplanted with bone marrow was used for comparison. Some of these series have been recently updated and also suggest an increased incidence of cGVHD. 31, 38 These results stress the importance of a longterm follow-up when analyzing the incidence of cGVHD after allo-PBT. Indeed, when analyzing late transplant complications, there is increasing awareness of the importance of using statistical tests that do not overestimate the incidence of this complication because of early complications (competing risk). 23 For this reason, we have analyzed the incidence of cGVHD using cumulative incidence estimates, and have obtained a lower incidence in both groups, although the statistical difference was maintained.
Another factor influencing the detection of differences in this complication when comparing allo-PBT and allo-BMT in case-control studies is the selection of variables to be matched. Data from the IBMTR 18 show that the strongest predictor of cGVHD after allo-BMT was the occurrence and severity of previous aGVHD. This factor has such an impact on subsequent cGVHD that it masks the influence of other factors affecting the risk. This study also showed that when the cohort of patients with or without grade I aGVHD was analyzed separately, it was possible to identify other factors associated with a significantly increased risk of developing cGVHD. These included a recipient age greater than 20 years, use of non-T cell-depleted marrow and use of allo-immune female donors for male recipients. Because of these facts, and given that preliminary data indicated that the incidence of aGVHD is similar after allo-PBT and allo-BMT, we chose the presence of previous aGVHD as one of the most important variables to be matched. This allowed us to determine that despite an identical incidence and severity of aGVHD in both groups, the incidence of cGVHD is greater in the PBT group, with de novo cGVHD constituting the most frequent subtype. The findings in our multivariate analysis confirm that aGVHD is the most important factor for the onset of cGVHD (P = 0.03) (relative risk of 4.4, 95% CI 1.2-16.4) ( Table 5 ). The limited number of patients precluded the analysis of predictive factors in the cohort of patients without aGVHD (n = 14). Other studies did not control previous aGVHD 36 involvement as a matched variable, thus showing a greater incidence in the PBT group than in the BMT group (grade 2-4 56% vs 37% after PBT and BMT, respectively). Although the greater incidence of aGVHD was not statistically significant, this fact could be partially responsible for a greater incidence of cGVHD in the PBT group.
In the present series, the high incidence of cGHVD does not seem to be influenced by a high occurrence of previous aGVHD, increased patient age, or a higher proportion of female donors for male patients.
The clinical characteristics of cGVHD in this series of allo-PBT did not differ substantially from those usually found after allo-BMT. 39 The skin, mouth and liver were the sites most frequently involved. The median interval between transplant and onset of cGVHD was 148 days (range 91-360), which was shorter than the 192 days (range 88-369) observed after allo-BMT, and similar to that reported by other authors in allo-PBT. 13, 14 It is interesting to note that in the IBMTR study, 40 late onset cGVHD was associated with a significantly higher probability of 2-year survival. This late occurrence of cGVHD in allo-PBT stresses once again the importance of long follow-up to shed light on the actual incidence of this complication in allo-PBT. Although cGVHD was the primary cause of death in only two cases in the PBT group and in one patient in the BMT group, and while it had no negative impact on overall survival, it was a major cause of morbidity. On the other hand, the low mortality associated with this disease improved the probability of long-term survival after BMT in a Seattle study, 41, 42 and this effect became more evident in a group of patients with a high probability of leukemic relapse. This reduction in relapse rate has not been confirmed in other preliminary studies. 31 In conclusion, although it is not possible to draw definitive conclusions from this retrospective comparative study, it is suggested that (1) the incidence of cGVHD after allo-PBT may be higher than after allo-BMT; (2) clinical characteristics of cGVHD in allo-PBT did not differ from those usually found after allo-BMT except for a greater incidence of the de novo form; and (3) although cGVHD was the primary cause of death in only two patients in the PBT group, it was a major cause of morbidity. Until the actual frequency of cGVHD in allo-PBT and its impact on disease-free survival, overall survival and morbidity are known, unmanipulated PBTs should not be routinely performed in place of allo-BMTs in the early phases of hematological malignancies, except when they are part of controlled trials.
